Basic information Safety Supplier Related

eperezolid

Basic information Safety Supplier Related

eperezolid Basic information

Product Name:
eperezolid
Synonyms:
  • eperezolid
  • N-[[(5S)-3-[3-fluoro-4-[4-(2-hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-Acetamide
  • PNU 100592
  • (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
  • U 100592
  • Eperezolid-d3
  • Eperezolid (PNU-100592
  • (S)-N-((3-(3-Fluoro-4-(4-(2-hydroxyacetyl)piperazin-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide
CAS:
165800-04-4
MF:
C18H23FN4O5
MW:
394.4
Mol File:
165800-04-4.mol
More
Less

eperezolid Chemical Properties

Melting point:
174-176℃
Boiling point:
701.2±60.0 °C(Predicted)
Density 
1.370±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
insoluble in EtOH; insoluble in H2O; ≥14.05 mg/mL in DMSO
form 
Powder
pka
13.84±0.10(Predicted)
color 
White to off-white
More
Less

eperezolid Usage And Synthesis

Uses

Antibacterial.

Uses

Eperezolid is an antimicrobial.

Biological Activity

mic50: 0.5, 1.0, 2.0, 1.0, 16.0 and 2.0 mg/l for pcptostreptococcus, propionibacterium acnes, ciostridium pefringens, clostridium dijiicile, bactrroidesjagilis, and fusobacterium, respectivleyanaerobic bacteria are a common cause of serious infections. anaerobic species which predominate in clinical infections include the bacteroides fragilis group, clostridium spp. and peptostreptococcus spp. the oxazolidinones are a novel class of synthetic antimicrobials inhibiting the initiation of protein synthesis. two compounds of this class, eperezolid and linezolid have been shown to inhibit enterococcus faecalis and enterococcus faecium.

in vitro

ninety per cent of all tested propionibacterium acnes (30 strains), peptostreptococccuj spp. (50 strains), c. perjringens (50 strains) and c. dficile (50 strains) were inhibited by <2 mg/l eperezolid. linezolid showed higher activity (mic90 4.0 mg/l) against b. jragilis (100 strains) compared to eperezolid (mic90 16 mg/l) [1].

in vivo

the in vivo effectiveness of eperezolid and linezolid against one strain each of enterococcus faecalis and vancomycin-resistant enterococcus faecium was examined in a rat intraabdominal abscess model. eperezolid was ineffective at doses of 25 mg/kg of body weight twice daily for the reductions in abscess bacterial density for e. faecalis. against e. faecium infections, intravenous eperezolid was effective, reducing densities approximately 2 log10 cfu/g [2].

References

[1] edlund c, oh h, nord ce. in vitro activity of linezolid and eperezolid against anaerobic bacteria. clin microbiol infect. 1999;5(1):51-53.
[2] schülin t, thauvin-eliopoulos c, moellering rc jr, eliopoulos gm. activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to enterococcus faecalis or vancomycin-resistant enterococcus faecium. antimicrob agents chemother. 1999;43(12):2873-6.
[3] schaadt rd, batts dh, daley-yates pt, pawsey sd, stalker dj, zurenko ge. serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid. diagn microbiol infect dis. 1997;28(4):201-4.

eperezolidSupplier

Wuxi Donghe Pharmaceutical Technology Co., Ltd. Gold
Tel
63313187 15358055255
Email
63313187@qq.com
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Email
info@adooq.com
LETOPHARM LIMITED
Tel
+86-21-5821 5861
Email
sales@letopharm.com
Nanjing XiZe Biotechnology CO., Ltd.
Tel
025-66023220 0086-15250997978
Email
1511893459@qq.com